Skip to main content

Table 1 Correlation of IL2RA mRNA expression with clinical and laboratory parameters in AML cohort

From: High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia

  N Percentage (%) IL2RA mRNA expression range Median IL2RA mRNA expression
Mean ± SE
p-value
Total 239      
Age group 0.312
 15–29 65 27.2 0.0014–3.780 0.0128 0.211 ± 0.603  
 30–49 113 47.3 0.0006–7.056 0.0097 0.304 ± 1.092  
 50–65 61 25.5 0.0013–12.870 0.0130 0.598 ± 2.184  
Gender 0.973
 Male 127 53.1 0.0006–12.870 0.0105 0.395 ± 1.573  
 Female 112 46.9 0.0006–6.140 0.0122 0.306 ± 1.108  
Blast percentage (%) 0.941
 ≥ 50 149 62.3 0.0006–8.540 0.0113 0.349 ± 1.247  
 20–49 90 37.7 0.0006–12.870 0.0114 0.361 ± 1.566  
WBC count 0.684
 ≥ 30 billion/L; high 58 34.7 0.0007–5.890 0.0136 0.341 ± 1.060  
 < 30 billion/L; low 109 65.3 0.0006–12.870 0.0106 0.430 ± 1.649  
AML type 0.605
 De novo AML 231 96.7 0.0006–12.870 0.0113 0.353 ± 1.392  
 Secondary AML 8 3.3 0.0033–1.560 0.0258 0.365 ± 0.642  
Fab subtypes 0.279
 Fab M0 6 2.6 0.0026–0.0468 0.0123 0.0172 ± 0.0161  
 Fab M1 32 13.6 0.0013–6.140 0.0136 0.402 ± 1.474  
 Fab M2 118 50.2 0.0006–4.120 0.0096 0.146 ± 0.576  
 Fab M4 43 18.3 0.0007–12.870 0.0175 0.605 ± 2.097  
 Fab M5 26 11.1 0.0006–8.540 0.0060 0.689 ± 1.981  
 Fab M6 10 4.3 0.0020–7.056 0.0521 0.749 ± 2.216  
 ND 4      
Cytogenetics groups 0.141
 Favorable-risk (CBF) 54 22.6 0.0006–3.780 0.0137 0.138 ± 0.543  
 Intermediate-risk 148 61.9 0.0006–12.870 0.0096 0.417 ± 1.547  
 Poor-risk 37 15.5 0.0026–7.056 0.0170 0.416 ± 1.473  
Flt3-ITD 0.001
 Flt3-ITD+ 38 19.8 0.0006–12.870 0.0820 0.871 ± 2.275  
 Flt3-ITD− 154 80.2 0.0006–7.056 0.0105 0.205 ± 0.918  
NPM1 0.818
 NPM1+ 36 18.8 0.0013–12.870 0.0117 0.452 ± 2.137  
 NPM1− 156 81.2 0.0006–7.056 0.0114 0.310 ± 1.058  
NPM1+FLT3-ITD 0.015
NPM1+FLT3-ITD 22 11.4 0.0013–0.0386 0.0056 0.0104 ± 0.0102  
NonNPM1+FLT3-ITD 170 88.6 0.0006–12.870 0.0128 0.377 ± 1.396  
CEBPA 0.034
 CEBPADM+ 19 9.9 0.0006–0.0848 0.0056 0.0138 ± 0.0197  
 CEBPADM 173 90.1 0.0006–12.870 0.0126 0.372 ± 1.389  
  1. N: number; ND: not determined; CEBPADM: CEBPA double mutations